Summary
Normal plasma, four coumarin plasmas and several artificially depleted “abnormal” control plasma were diluted 1∶1, 1∶2, 1∶3, 1∶5, 1∶10 in Michaelis buffer. Variable aliquots of such dilutions were the mixed with several tissue thromboplastins and the clotting time measured.
Four thromboplastin reagents were used: Thrombotest, Normotest, Manchester Thromboplastin and Simplastin A. Using Manchester Thromboplastin adsorbed normal plasma was added to the system too.
The “inhibitory effect” present in the system was evaluated by means of conventional units “i” (1 U=4 cm.).
Using Thrombotest, Normotest, Manchester Thromboplastin and Simplastin A the average inhibition observed with the coumarin plasmas was 1.30 U, 0.42 U, 1.10 U and 0.75 U, respectively.
The average inhibition observed with artificially depleted control plasmas was 0.03 U, 0.08 U, 0.33 U and 0.38 U, respectively.
The studies indicate that artificially depleted control plasmas behave differently from coumarin plasmas in a dilution curve system and therefore cannot be considered as “equivalent” to them in coagulation studies.
Zusammenfassung
Normales Plasma, vier Cumarin-Plasmen und mehrere, künstlich durch Entzug „abnormal” gemachte Kontrollplasmen wurden in Michaelis-Pufferlösung 1∶1, 1∶2, 1∶3, 1∶5, 1∶10 verdünnt. Variable Aliquots derartiger Verdünnungen wurden dann mit mehreren Gewebe-Thromboplastinen gemischt und die Gerinnungszeit wurde gemessen.
Vier Thromboplastinreagentien wurden verwendet: Thrombotest, Normotest, Manchester Thromboplastin und Simplastin A. Bei Verwendung von Manchester Thromboplastin wurde adsorbiertes, normales Plasma der Anordnung zugesetzt.
Der „Hemmeffekt” in dieser Anordnung wurde mittels der konventionellen Einheiten „i” (1 E=4 cm) bewertet.
Bei Verwendung von Thrombotest, Normotest, Manchester Thromboplastin und Simplastin A betrug die beobachtete durchschnittliche Hemmung bei den Cumarinplasmen 1,30 E, bzw. 0,42 E, 1,10 E und 0,75 E. Die beobachtete Durchscnittshemmung bei den künstlich verarmten Kontrollplasmen betrug jeweils 0,03 E, 0,08 E, 0,33 E und 0,38 E. Die Untersuchungen zeigen, daß Kontrollplasmen, die durch Entzug künstlich verändert wurden, sich in einem Verdünnungskurvensystem unterschiedlich von Cumarinplasmen verhalten und daß sie daher in Koagulations-untersuchungen nicht als „gleichwertig” betrachtet werden können.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bangham, D. R., R. Biggs, M. Brozovic and K. W. E. Denson: Draft report of a collaborative study of two thromboplastinş (including the use of common abnormal plasma). Thromb. Diath. Haemorrh. Suppl.40, 341 (1970).
Dixon, M. and E. C. Webb: Enzymes. Sec. Edition, pag. 54–166, Longmans Co., London 1964.
Girolami, A., A. Brunetti and G. Bareggi: Factor X level in coumarin treated patient and in factor X deficiency as assayed with different techniques. Blut25, 77 (1972).
Girolami, A., A. D. Muller and H. C. Hemker: Lack of P.I.V.K.A. effect in the abnormal factor X (factor X Friuli) coagulation disorder. Haemostasis1, 23 (1973).
Girolami, A., A. Brunetti, L. De Marco and A. Fioretti: Dilution curve studies in prothrombin complex factors deficiencies or abnormalities. (In preparation.)
Hemker, H. C., J. J. Velkamp and E. A. Loeliger: Kinetic aspects of the interaction of blood clotting enzymes. III. Demonstration of an inhibitor of prothrombin conversion in vitamin K deficiency. Thromb. Diath. Haemorrh.19, 346–363 (1968).
Hemker, H. C., and P. W. Hemker: Kinetic aspects of the interaction of blood clotting enzymes. IV. Kinetics of comparative inhibition in clotting tests. Thromb. Diath. Haemorrh.19, 361 (1968).
Hemker, H. C. and A. D. Muller: Kinetic aspects of the interaction of blood clotting enzymes. VI. Localization of the site of blood coagulation inhibition by the protein induced by vitamin K absence (P.I.V.K.A.). Thromb. Diath. Haemorrh.20, 78 (1968).
Hemker, H. C.: The Thrombotest dilution curve and its diagnostic significance. In: Human blood coagulation, Hemker, H. C., Loeliger E. A., Veltkamp J. J. (Edt.), pag. 365–368, Leiden University Press, 1969.
Korsan-Bengtsen, K.: Comparison between various methods used to control dicumarol therapy. Acta Med. Scand.188, 327–335 (1970).
Lineweaver, H. and D. Burk: The determination of enzyme association constants. J. Amer. Chem. Soc.56, 658 (1934).
Loeliger, E. A., J. Meuwisse-Braun, H. Muis, F. J. J. Buitendijk, J. J. Veltkamp and H. C. Hemker: Laboratory control of oral anticoagulatn. Definition of therapeutic range in terms of different thromboplastin preparations. Thromb. Diath. Haemorrh.23, 569 (1970).
Miale, J. B. and D. J. La Fond: Prothrombin time standardization. Am. J. Clin. Path.52, 154 (1969).
Miale, J. B. and J. W. Kent: Standardization of the therapeutic range for oral anticoagulants based on standard reference plasmas. Am. J. Clin. Path.57, 80 (1971).
Owren, P. A.: “Thrombotest”. A new method for the controlling anticoagulant therapy. Lancet2, 754 (1959).
Owren, P. A.: The interrelationship between Normotest and Thrombotest. Farmakoterapi25, 13 (1969).
Poller, L. and J. M. Thomson: National survery of value of plasma standards for anticoagulant therapy. Brit. Med. J.2, 88 (1968).
Poller, L.: Anticoagulant therapy standards: Results of two national surveys. Thromb. Diath. Haemorrh. Suppl.35, 115 (1969).
Rodman, Th. and B. H. Pastor: Control of anticoagulant therapy with the Thrombotest. Am. J. Med. Ass.180, 739 (1962).
Warner-Lambert Laboratories, Angiolini S.p.A. Pers. comun., Febr. 1973.
Zucker, S., M. H. Cathey, P. J. Sox and E. C. Hall: Standardization of laboratory tests for controlling anticoagulant therapy. Am. J. Clin. Path.53, 348 (1940).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Girolami, A., Brunetti, A. & Patrassi, G. Dilution curves studies in coumarin plasmas and in artificially depleted abnormal control plasmas. Blut 28, 351–359 (1974). https://doi.org/10.1007/BF01631522
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01631522